<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135781</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-KAL-GC-04</org_study_id>
    <nct_id>NCT04135781</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer</brief_title>
  <official_title>Adjuvant Nab-paclitaxel Plus S-1 Versus Capecitabine Plus Oxaliplatin for Patients With Stage III Gastric Cancer After D2 Gastrectomy : a Randomised，Open-label, Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label phase III study. The treatment was compare the efficacy and
      safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX)
      treating stage Ⅲ gastric cancer as adjuvant setting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label phase III study. The treatment was compare the efficacy and
      safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX)
      treating stage Ⅲ gastric cancer as adjuvant setting. The primary endpoint is the 3-year
      diseases-free survival (DFS) rate. The secondary endpoints are the overall survival (OS) and
      safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 years Diseases-free Survival rate(3 years-DFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>DFS is defined as time from the date of inclusion up to the date of disease progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall survival is defined as time from the start of treatment until death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by number and grade of adverse events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Summary adverse events according to NCI-CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">616</enrollment>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>AS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A：nab paclitaxel （120mg/m2；iv；d1，8）+S-1 （&lt;1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）Q3W；up to eight cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B：Capetabine（1000 mg/m2 po, d1-14 bid ）+ Oxaliplatin（130mg/m2 , iv, d1）Q3W；up to eight cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab paclitaxel</intervention_name>
    <description>nab paclitaxel （120mg/m2；iv；d1，8）</description>
    <arm_group_label>AS</arm_group_label>
    <other_name>albumin bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur</intervention_name>
    <description>S-1 （&lt;1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）</description>
    <arm_group_label>AS</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin（130mg/m2 , iv, d1）</description>
    <arm_group_label>XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capetabine（1000 mg/m2 po, d1-14 bid ）</description>
    <arm_group_label>XELOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of 18-75 years;

          2. Histological diagnosis of stage III gastric adenocarcinoma and Gastroesophageal
             junction of the stomach;

          3. Patients are required to provide a pathologically confirmed diagnosis report and
             provide 4-5 histological white films obtained at baseline;;

          4. Patients underwent D2 radical resection within 6 weeks prior to random enrollment; and
             R0 resection criteria were achieved;

          5. Ability to perform chemotherapy within 7 days of enrollment in the randomized group;

          6. No prior anti-tumor treatment (including systemic chemotherapy and local
             radiotherapy), except for initial gastrectomy for primary lesions;

          7. ECOG performance status of 0-1;

          8. Haematological status: absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT)
             ≥100×109 /L, hemoglobin(HB) ≥90 g/L;WBC ≥3.0×109 /L;And no bleeding tendency;

          9. Liver function: alanine glutamate transaminase (ALT) and glutamate transaminase (AST)
             ≤2.5 x upper limit of normal range (ULN), alkaline phosphatase ≤2.5 x upper limit of
             normal range (ULN)；total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN),
             or≤3 x upper limit of normal range (ULN) when with Gilbert's syndrome;

         10. kidney function: Creatinine(Cr)≤1.5 x upper limit of normal range(ULN) or Creatinine
             clearance &gt;60 ml/min (calculated according to Cockroft-Gault)

         11. Able and willing to comply with the study plans in this protocol and sign the informed
             consent;

        Exclusion Criteria:

          1. Treat with any other study drug or participate in another clinical trial with
             therapeutic intent within 28 days prior to enrollment;

          2. postoperative complications requiring clinical intervention and affecting treatment,
             such as stomach cramps, dumping syndrome;

          3. Patients known to be allergic or intolerant to clinical trial drugs;

          4. investigator believes will affect the subject's treatment regimen, uncontrolled
             serious medical diseases, including severe heart disease (such as the New York Heart
             Association (NYHA) Level II or more Congestive heart failure), cerebrovascular
             disease, uncontrolled diabetes, uncontrolled high blood pressure, uncontrolled
             infection；

          5. Known active infection with HIV, hepatitis B or hepatitis C;

          6. Other serious and uncontrolled non-malignant disease; except adequately treated
             cervical carcinoma in situ, non-melanoma skin Localized prostate cancer after cancer
             and radical surgery (PSA ≤ 10 ng/ml); no recurrence or metastasis was found based on
             imaging follow-up results and any disease-specific tumor markers;

          7. accompanied by dysphagia, complete or incomplete gastrointestinal obstruction, active
             gastrointestinal bleeding, perforation;

          8. Female patients during pregnancy or lactation, who are refused to receive
             contraception during the childbearing age;

          9. The investigator judges patients who are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng xiangdong, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng xiangdong, PhD</last_name>
    <phone>0571-88128041</phone>
    <email>Chengxd516@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu pengfei, PhD</last_name>
    <phone>0571-88128041</phone>
    <email>ypfzmu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangdong Cheng, MD，PhD</last_name>
      <phone>+86-571-88128202</phone>
      <email>Chengxd516@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiangdong Cheng, MD，PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Pengfei, MD，PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 20, 2019</study_first_submitted>
  <study_first_submitted_qc>October 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Xiangdong Cheng</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>nab-paclitaxel</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

